Status:
COMPLETED
Uric Acid and the Endothelium in CKD
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Kidney Disease
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study will test the hypothesis that uric acid impairs the function of vessels in patients with kidney disease
Detailed Description
The purpose of the study is to understand the effect of lowering serum uric acid levels on vascular function in individuals with chronic kidney disease by comparing the effects of: 1\) Allopurinol th...
Eligibility Criteria
Inclusion
- Individuals with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates between 30-60 mL/min/ 1.73m2
- Elevated uric acid levels
- Age range: more than 18 years old
- Ability to give informed consent
- Albumin \> 3.0 g/dL
- BMI \< 40 kg/m2
Exclusion
- Life expectancy \< 1.0 years
- Expected to undergo living related kidney transplant in 6 months
- Pregnant, breast feeding, or unwilling to use adequate birth control
- History of severe liver disease
- History of severe congestive heart failure
- History of hospitalizations within 3 months
- Active infection, on antibiotics
- History of Warfarin Use or other medications that are contraindicated with allopurinol
- Uncontrolled hypertension
- History of acute gout on Allopurinol
- History of adverse reaction to Allopurinol
- Immunosuppressive therapy within the last 1 yr
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01228903
Start Date
October 1 2010
End Date
September 1 2016
Last Update
June 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado at Denver
Aurora, Colorado, United States, 80045